SCHEMBL6509825

SCHEMBL6509825

CCCC[Si](C)(C)Oc1cccc2cc(Br)ccc12

nearest known ligand 0.40

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
LMNA P02545 3/20 0.40
SMN1; SMN2 Q16637 3/20 0.40
MAPT P10636 2/20 0.37
EGFR P00533 1/20 0.36
RXFP1 Q9HBX9 1/20 0.35
HTR1B P28222 2/20 0.35
CASP1 P29466 1/20 0.34
CASP3 P42574 1/20 0.34
CASP7 P55210 1/20 0.34
CASP6 P55212 1/20 0.34
CASP8 Q14790 1/20 0.34
ACHE P22303 1/20 0.33
HTR1D P28221 1/20 0.33
MCHR1 Q99705 1/20 0.33
FBP1 P09467 1/20 0.32
ATM Q13315 1/20 0.32
SLC6A2 P23975 1/20 0.32
SLC6A4 P31645 1/20 0.32
NPC1 O15118 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL17919856 0.79 HTR1B (0.51) EGFRHTR1BHTR1DMCHR1SLC6A4
SCHEMBL15565685 0.76 HTR1B (0.49) MAPTEGFRHTR1BHTR1DMCHR1
SCHEMBL6585052 0.73 MEN1 (0.40) LMNASMN1; SMN2MAPTATMNPC1
SCHEMBL27674309 0.73 CNR1 (0.41) LMNASMN1; SMN2HTR1BHTR1DMCHR1
SCHEMBL9322884 0.73 GAA (0.40) HTR1BHTR1DMCHR1NPC1
SCHEMBL6121483 0.73 NCEH1 (0.38) LMNAEGFRRXFP1CASP1CASP3
SCHEMBL6312903 0.71 KDM4E (0.51) LMNASMN1; SMN2EGFRRXFP1ACHE
SCHEMBL16417118 0.70 CYP1A2 (0.56) MAPTACHEMCHR1
SCHEMBL6585059 0.70 MGLL (0.43) LMNASMN1; SMN2MAPTNPC1
SCHEMBL20744686 0.69 BCHE (0.45) HTR1BHTR1DMCHR1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2005108338-A1 NOVEL THERAPEUTIC AGENTS FOR THE TREATMENT OF CANCER, METABOLIC DISEASES AND SKIN DISORDERS AUSPEX PHARMACEUTICALS (US) 2005-11-17 WO disclosed